Compare iShares Core S&P 500 ETF (IVV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $771.05 (market cap $896.34B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares Core S&P 500 ETF is far larger — about 183.7× Travere Therapeutics Inc. Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IVV | TVTX | |
|---|---|---|
Market Cap | $896.34B | $4.88B |
Volume | 3,965,666 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $67.52 |
52-Week Low | $634.93 | $26.79 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.42 with minimal daily change. Technical analysis shows a bullish trend with strong moving average support, though RSI indicates potential overbought conditions near-term. The ETF benefits from broad market exposure amid expectations of continued corporate profit growth, with S&P 500 earnings projected to rise 35% in 2026 according to 24/7 Wall Street on October 3, 2026.
Outlook remains positive given historical seasonal trends and strong institutional support, but risks include concentration in top holdings and potential profit growth deceleration. The ETF's low-cost structure and diversification provide stability, though market volatility and economic shifts could challenge near-term performance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
